IBRX
ImmunityBio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$8.08
−1.34%Aug 20, 2026, 07:24 UTC
Bell & Brown Wealth Advisors LLC acquired a new stake in ImmunityBio, Inc. by purchasing 75,050 shares worth approximately $657,000 in the second quarter.
Source:Aug 20, 2026, 07:23 UTC
Bank of America Corp DE increased its stake in ImmunityBio, Inc. by 2.7% during the first quarter, acquiring an additional 65,340 shares, according to its SEC disclosure.
Source:Aug 17, 2026, 05:17 UTC
Goldman Sachs increased its stake in Capricor Therapeutics by 73% to 1.58 million shares valued at $38 million, and disclosed holdings in Sellas Life Sciences and ImmunityBio totaling nearly $75 million.
Source:Aug 4, 2026, 11:30 UTC
ImmunityBio reported record net product revenue of $50.7 million for Q2 2026, up 92% year-over-year, with first-half revenue up 121% to $94.8 million.
Jul 29, 2026, 22:45 UTC
The Emirates Drug Establishment of the United Arab Emirates granted marketing authorization for ImmunityBio's ANKTIVA across BCG-unresponsive non-muscle invasive bladder cancer and metastatic non-small cell lung cancer.
Source:Jun 5, 2026, 21:56 UTC
ImmunityBio director Simon Barry J. sold 23,033 shares of common stock worth $165,305 on June 4, 2026, under a Rule 10b5-1 trading plan.
Source: